Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia

(2021) Patrick A. Brown et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia

(2021) Franco Locatelli et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

(2020) Norman J. Lacayo et al.   BLOOD

Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia

(2020) Franco Locatelli et al.   LEUKEMIA

Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation

(2019) Brice Mouttet et al.   HAEMATOLOGICA

BCL-2 is a Therapeutic Target For Hypodiploid B-Lineage Acute Lymphoblastic Leukemia

(2019) Ernesto Diaz-Flores et al.   CANCER RESEARCH

Aneuploidy in children with relapsed B-cell precursor acute lymphoblastic leukaemia: clinical importance of detecting a hypodiploid origin of relapse

(2019) Stefanie Groeneveld-Krentz et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bortezomib reinduction chemotherapy in high‐risk ALL in first relapse: a report from the Children's Oncology Group

(2019) Terzah M. Horton et al.   BRITISH JOURNAL OF HAEMATOLOGY

Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia

(2019) Salih Demir et al.   HAEMATOLOGICA

Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial

(2019) Catriona Parker et al.   Lancet Haematology

Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

(2019) Fotini Vogiatzi et al.   BLOOD

Efficacy and safety of a bortezomib and reduced‐intensity cytarabine‐based protocol, TMC ALLR1, for relapsed childhood ALL in India

(2019) Prakriti Roy et al.   BRITISH JOURNAL OF HAEMATOLOGY

Clinical Experience with Venetoclax in Combination with Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

(2019) Guillaume Richard-Carpentier et al.   Clinical Lymphoma Myeloma & Leukemia

Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics

(2019) Cornelia Eckert et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia

(2018) Karen L. Bride et al.   BLOOD

Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia

(2018) David O’Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

(2018) Lia Gore et al.   Blood Cancer Journal

Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia

(2016) Julie A. E. Irving et al.   BLOOD

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research

(2015) Michael J. Burke et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment

(2015) C Eckert et al.   LEUKEMIA

Genomics and drug profiling of fatal TCF3-HLF−positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options

(2015) Ute Fischer et al.   NATURE GENETICS

Notch1-induced T cell leukemia can be potentiated by microenvironmental cues in the spleen

(2014) Shihui Ma et al.   Journal of Hematology & Oncology

Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia – Prospective Open Cohort Analyses of the ALLR3 Trial

(2014) Ashish Narayan Masurekar et al.   PLoS One

The genomic landscape of hypodiploid acute lymphoblastic leukemia

(2013) Linda Holmfeldt et al.   NATURE GENETICS

Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia

(2012) S Krentz et al.   LEUKEMIA

Mutations and Deletions of the TP53 Gene Predict Nonresponse to Treatment and Poor Outcome in First Relapse of Childhood Acute Lymphoblastic Leukemia

(2011) Jana Hof et al.   JOURNAL OF CLINICAL ONCOLOGY

Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group

(2010) D. R. Freyer et al.   BLOOD

Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90

(2010) Gesche Tallen et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial

(2010) Catriona Parker et al.   LANCET

Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

(2008) Elizabeth A. Raetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group

(2008) Peter Bader et al.   JOURNAL OF CLINICAL ONCOLOGY

Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study

(2008) K Nguyen et al.   LEUKEMIA